Table 1.
Chemotherapy regimens with the most widely used fluoropyrimidines by tumor type
| Tumor | Scheme | Dose | Frequency (days) |
|---|---|---|---|
| Adjuvant colon | CAP | CAP 1.000–1.250 mg/m2/12 h, 14 days | Every 21 |
| CAPOX |
CAP 850–1.000 mg/m2/12 h, 14 days OX 130 mg/m2, day 1 |
Every 21 | |
| mFOLFOX-6 |
Leucovorin 400 mg/m2 5-FU 400 mg/m2 bolus and 2.400 mg/m2 c.i. 46 h OX 85 mg/m2, day 1 |
Every 14 | |
| Neoadjuvant rectum | CAP and RT |
CAP 825 mg/m2/12 h and RT Monday to Friday for 5 weeks |
Daily |
| Metastatic colorectal* | CAPOX** and mFOLFOX-6 | Same as in adjuvant | |
| mFOLFIRI |
Leucovorin 400 mg/m2 5-FU 400 mg/m2 bolus and 2.400 mg/m2 c.i. 46 h Irinotecan 180 mg/m2, day 1 |
Every 14 | |
| Localized anal canal | 5-FU, MIT-C and RT |
5-FU 1.000 mg/m2/day c.i., days 1–4 MIT-C 10 mg/m2, day 1 × 2 cycles |
Every 21 |
| Localized oesophageal epidermoid | Cisplatin, 5-FU and RT |
Cisplatin 75 mg/m2, day 1 5-FU 800 mg/m2/day c.i., days 1–5 |
Every 21 |
| Perioperative gastric | FLOT |
5-FU 2.600 mg/m2 c.i. 24 h Leucovorin 200 mg/m2 OX 85 mg/m2 Docetaxel 50 mg/m2, day 1 |
Every 14 |
| Metastatic oesophageal and gastric | Cisplatin and CAP |
Cisplatin 80 mg/m2, day 1 CAP 1.000 mg/m2/12 h, 14 days ± trastuzumab in HER2 + + + |
Every 21 |
| EOX |
Epirubicin 50 mg/m2 OX 130 mg/m2 CAP 625 mg/m2/12 h continuous |
Every 21 | |
| AL-SARRAF, TPF, XELOX and FOLFOX |
Same as metastatic head and neck and adjuvant colon |
||
| Pancreas | FOLFIRINOX |
Leucovorin 400 mg/m2 5-FU 400 mg/m2 bolus and 2.400 mg/m2 c.i. 46 h Irinotecan 150 mg/m2 OX 85 mg/m2, day 1 |
Every 14 |
| Localized breast | FEC 100 |
5-FU 500 mg/m2 Epirubicin 100 mg/m2 Cyclophosphamide 600 mg/m2, day 1 |
Every 28 |
| Metastatic breast | CAP and lapatinib |
CAP 1.000 mg/m2/12 h, 14 days Lapatinib 1.250 mg/m2/day continuous |
Every 21 |
| CMF |
Cyclophosphamide 600 mg/m2 Methotrexate 40 mg/m2 5-FU 600 mg/m2, day 1 |
Every 21 | |
| TC |
Docetaxel 75 mg/m2, day 1 CAP 1.250 mg/m2/12 h, 14 days |
Every 21 | |
| CAP and trastuzumab |
CAP 1.000 mg /m2/12 h, 14 days Trastuzumab 6 mg/kg, day 1 (loading dose: 8 mg/kg) |
Every 21 | |
| Neoadjuvant head and neck | TPF |
Docetaxel 75 mg/m2 Cisplatin 75–100 mg/m2 5-FU 1.000 mg/m2/day c.i., days 1–4, day 1 |
Every 21 |
| Metastatic head and neck | EXTREME |
Cisplatin 100 mg/m2, day 1 5-FU 1.000 mg/m2/day c.i., days 1–4 Cetuximab 250 mg/m2, days 1, 8 and 15 (loading dose: 400 mg/m2) |
Every 21 |
| AL-SARRAF |
Cisplatin 100 mg/m2 5-FU 1.000 mg/m2/day c.i., days 1–5 |
Every 21 |
5-FU 5-fluorouracil, AL-SARRAF cisplatin and 5-fluorouracil, CAP capecitabine, CAPOX capecitabine and oxaliplatin, CMF cyclophosphamide, methotrexate and 5-fluorouracil, EGFR epidermal growth factor receptor, EOX epirubicin, oxaliplatin and capecitabine, EXTREME cisplatin, 5-fluorouracil and cetuximab, FEC 5-fluorouracil, epirubicin and cyclophosphamide, FLOT 5-fluorouracil, leucovorin, oxaliplatin and docetaxel, FOLFIRI leucovorin, 5-fluorouracil and irinotecan, FOLFIRINOX leucovorin, 5-fluorouracil, irinotecan and oxaliplatin, FOLFOX leucovorin, 5-fluorouracil and oxaliplatin, c.i. continuous infusion, MIT-C mitomycin C, OX oxaliplatin, RT radiotherapy, TC docetaxel and capecitabine, TPF docetaxel, cisplatin and 5-fluorouracil
*Associated with anti-VEGF (bevacizumab or aflibercept) or anti-EGFR (cetuximab or panitumumab) in patients with RAS wild type
**The use of capecitabine in combination with anti-EGFR is not approved